QuidelOrtho Corporation — FY2023 Form 10-K
Reporting period: Fiscal year ended December 31, 2023. This is an annual report, not a standalone fourth-quarter filing; the supplied filing text does not provide clear Q4-only financial results. QuidelOrtho’s 2023 results include a full year of Ortho operations, compared with only part of 2022 following the May 2022 combination.
Business context and financial performance
QuidelOrtho sells diagnostic instruments, assays and related services across Labs, Transfusion Medicine, Point of Care and Molecular Diagnostics. It serves customers in more than 130 countries and reports North America, EMEA and China as its reportable segments.
| Metric | FY2023 | FY2022 |
|---|---|---|
| Total revenue | $2,997.8 million | $3,266.0 million |
| Cost of sales, excluding intangible amortization | $1,503.4 million; 50.2% of revenue | $1,330.0 million; 40.7% of revenue |
| Operating income | $139.1 million | $843.7 million |
| Net income (loss) | $(10.1) million | $548.7 million |
| Diluted earnings (loss) per share | $(0.15) | $9.56 |
| Cash from operating activities | $280.2 million | $885.3 million |
| Capital expenditures, net of government assistance | Approximately $196 million | Approximately $123 million |
Gross margin, calculated from reported revenue and cost of sales, was approximately 49.8% in 2023 versus 59.3% in 2022. Operating margin was approximately 4.6% versus 25.8%. The filing reports no consolidated Adjusted EBITDA figure in the cited results; segment Adjusted EBITDA totaled $1,252.9 million in 2023 versus $1,843.1 million in 2022, before corporate costs and other reconciling items.
Material changes and liquidity
- Revenue declined 8% year over year, primarily as COVID-19 test demand fell. Point of Care revenue dropped 54% to $892.2 million; Molecular Diagnostics declined 67% to $31.7 million. Labs revenue rose 74% to $1,425.4 million and Transfusion Medicine rose 65% to $648.5 million, largely reflecting the full-year inclusion of Ortho.
- Respiratory products generated 24% of revenue in 2023, compared with 57% in 2022 and 81% in 2021. Management attributes the decline to lower demand following the end of the U.S. public health emergency and the transition of COVID-19 to an endemic environment.
- Operating income fell substantially amid lower respiratory sales, a less favorable product mix, higher relative cost of sales, and increased acquired-intangible amortization and integration expenses. Interest expense, net, rose to $147.6 million from $75.7 million.
- Cash and cash equivalents were $118.9 million at year-end, down from $292.9 million; cash, cash equivalents and marketable securities totaled $174.7 million. Working capital was $476.7 million, including current marketable securities.
- Total borrowings were $2,414.6 million, including a $2,420.2 million Term Loan before unamortized financing costs and other borrowings. The company had $787.1 million available under its $800 million revolver, net of letters of credit. Debt facilities mature May 27, 2027; the company reported compliance with financial covenants at year-end.
Outlook, risks and unusual items
- Management expects respiratory-product demand to remain variable, with seasonal patterns, competition and pricing pressure affecting results. It provided no specific numerical revenue or earnings guidance in the supplied text.
- Management expects continued investment in R&D, next-generation platforms and assays, and digital and automation capabilities. It states that cash, operating cash flow and revolver availability should fund near-term needs for at least 12 months.
- Supply, production, logistics and labor challenges persisted, although their frequency and significance had lessened by the fourth quarter of 2023. Raw-material pricing pressure was less severe than in 2022; some inputs remain available from limited sources.
- In February 2024, the company initiated a planned wind-down of its U.S. donor-screening VIP platform and microplate assays, citing lower growth and margin prospects. Existing customers and contractual commitments are to be supported; non-U.S. donor screening is unaffected.
- FY2023 included a $19.2 million third-party settlement award related to a collaboration agreement. The company also recorded a $19.0 million income tax benefit despite a pretax loss, with the effective tax rate affected by tax settlements, valuation allowances and GILTI.
- Key risks include further respiratory-product declines, competition and pricing, integration and transformation execution, supply-chain interruptions, regulatory clearances and EUAs, cybersecurity and data protection, foreign exchange, and debt service and covenant flexibility. The company reported no material cybersecurity threats or incidents identified during the fiscal year.
- The auditor’s critical audit matter was the contractual rebate reserve, which requires estimates using distributor data and end-user sales mix. The auditor issued unqualified opinions on the financial statements and internal controls; management also concluded controls were effective.
Important facts for investors to verify
- Whether respiratory testing demand, price and product mix stabilize, and how that affects revenue and margins given respiratory products’ 24% revenue share.
- How much of reported growth in Labs and Transfusion Medicine reflects underlying demand versus the acquisition comparison, and whether integration savings or growth opportunities materialize.
- Progress and costs of the U.S. donor-screening wind-down, including customer transitions and any associated charges or obligations.
- Debt repayment capacity, interest-rate exposure and covenant headroom; the 2027 maturity profile is concentrated, with $1,973.3 million of scheduled repayments shown for 2027.
- Cash conversion and working-capital needs, particularly inventory, alongside the company’s planned instrument placements under its reagent-rental model.
- Assumptions and sensitivity in rebate reserves, tax-asset realizability and goodwill valuations; the company reported a $274.7 million deferred-tax valuation allowance and no goodwill impairment in its 2023 test.